Pembrolizumab monotherapy versus chemotherapy in platinum-pretreated, recurrent or metastatic nasopharyngeal cancer (KEYNOTE-122): an open-label, randomized, phase III trial
Journal
Annals of oncology : official journal of the European Society for Medical Oncology
Journal Volume
34
Journal Issue
3
Date Issued
2023-03
Author(s)
Chan, A T C
Lee, V H F
Ahn, M-J
Chong, W Q
Kim, S-B
Ho, G F
Caguioa, P B
Ngamphaiboon, N
Ho, C
Aziz, M A S A
Ng, Q S
Yen, C-J
Soparattanapaisarn, N
Ngan, R K-C
Kho, S K
Tiambeng, M L A
Yun, T
Sriuranpong, V
Algazi, A P
Cheng, A
Massarelli, E
Swaby, R F
Saraf, S
Yuan, J
Siu, L L
Abstract
Pembrolizumab previously demonstrated robust antitumor activity and manageable safety in a phase Ib study of patients with heavily pretreated, programmed death ligand 1 (PD-L1)-positive, recurrent or metastatic nasopharyngeal carcinoma (NPC). The phase III KEYNOTE-122 study was conducted to further evaluate pembrolizumab versus chemotherapy in patients with platinum-pretreated, recurrent and/or metastatic NPC. Final analysis results are presented.
Subjects
immunotherapy; nasopharyngeal cancer; pembrolizumab; programmed death-1 (PD-1)
SDGs
Type
journal article